Pacer Advisors
CGON icon

Pacer Advisors’s CG Oncology CGON Stock Holding History

Pacer Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Buy
+839
New +$54.8K ﹤0.01% 1992
2024
Q3 		– Sell
-290
Closed -$9.15K – 2588
2024
Q2 		$9.15K Buy
+290
New +$10.1K ﹤0.01% 3563

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pacer Advisors's CGON Position: Q2 2026 in Review

Pacer Advisors opened a new position in CG Oncology (CGON) in Q2 2026: 839 shares worth $60K. The stake represents ﹤0.01% of the portfolio and ranks #1992 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in CGON as recently as Q2 2024.

Pacer Advisors first reported a position in CGON in Q2 2024 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Pacer Advisors held 839 shares of CG Oncology worth $60K as of Q2 2026.
  • CG Oncology was a new Pacer Advisors position in Q2 2026.
  • CG Oncology made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1992 holding.
  • Pacer Advisors first reported a position in CG Oncology in Q2 2024 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.